Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
29 Janeiro 2024 - 9:03AM
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage
biotechnology company developing therapies for patients with kidney
disease (the “Company or “Unicycive”), today announced that two
presentations related to UNI-494 will be presented at the 29th
International Conference on Advances in Critical Care Nephrology
AKI and CRRT 2024 taking place March 12-15, 2024, in San Diego, CA.
Shalabh Gupta, MD, Chief Executive Officer of
Unicycive, commented, “We are looking forward to presenting data on
the efficacy of our second clinical stage program UNI-494 in animal
models of delayed graft function, a manifestation of acute kidney
injury (AKI) that occurs during kidney transplantation resulting in
loss of kidney function. We are also presenting a poster describing
our ongoing Phase 1 clinical trial design for UNI-494 in healthy
volunteers. Based on the results from this trial, we will determine
the best path forward for the program. While our primary focus is
on advancing our lead drug, OLC (Oxylanthanum Carbonate) towards a
New Drug Application submission, we continue to build a body of
data on UNI-494 as it progresses through its first clinical
trial.”
|
|
Title: |
Intravenous Administration of UNI-494 Ameliorates Acute
Kidney Injury in Rat Model of Delayed Graft Function |
Lead Author: |
Satya Medicherla, Ph.D. |
Type: |
Oral Presentation |
Date/Time: |
Tuesday, March 12, 2024 / 5:30 –
7:30 p.m. PT |
|
|
Title: |
UNI-494 Phase I Safety,
Tolerability and Pharmacokinetics: Trial in Progress |
Lead Author: |
Guru Reddy, PH.D. |
Type: |
Poster |
Date/Time: |
March 12th from 5:30 – 7:30 p.m.
PT and March 13th from 6:00 – 8:00 p.m. PT |
|
|
About UNI-494
UNI-494 is a novel nicotinamide ester derivative
and a selective ATP-sensitive mitochondrial potassium channel
activator. Mitochondrial dysfunction plays a critical role in the
progression of acute kidney injury and chronic kidney disease.
UNI-494 has a novel mechanism of action that restores mitochondrial
function and may be beneficial for the treatment of several
diseases including kidney disease. Unicycive is currently
conducting a Phase 1 dose-ranging safety study in healthy
volunteers in the United Kingdom that is expected to complete this
year. UNI-494 is protected by issued patent(s) in the U.S. and
Europe and a wide range of patent applications worldwide.
About Unicycive
Therapeutics
Unicycive Therapeutics is a biotechnology
company developing novel treatments for kidney diseases.
Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a
novel investigational phosphate binding agent being developed for
the treatment of hyperphosphatemia in chronic kidney disease
patients on dialysis. UNI-494 is a patent-protected new chemical
entity in late preclinical development for the treatment of acute
kidney injury. For more information, please visit
Unicycive.com and follow us on LinkedIn and YouTube.
Forward-looking statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
using words such as "anticipate," "believe," "forecast,"
"estimated" and "intend" or other similar terms or expressions that
concern Unicycive's expectations, strategy, plans or intentions.
These forward-looking statements are based on Unicycive's current
expectations and actual results could differ materially. There are
several factors that could cause actual events to differ materially
from those indicated by such forward-looking statements. These
factors include, but are not limited to, clinical trials involve a
lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of
future trial results; our clinical trials may be suspended or
discontinued due to unexpected side effects or other safety risks
that could preclude approval of our product candidates; risks
related to business interruptions, which could seriously harm our
financial condition and increase our costs and expenses; dependence
on key personnel; substantial competition; uncertainties of patent
protection and litigation; dependence upon third parties; and risks
related to failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties related to market conditions and other factors
described more fully in the section entitled ‘Risk Factors’ in
Unicycive’s Annual Report on Form 10-K for the year ended December
31, 2022, and other periodic reports filed with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Unicycive
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Investor Contact:
ir@unicycive.com (650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
Unicycive Therapeutics (NASDAQ:UNCY)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Unicycive Therapeutics (NASDAQ:UNCY)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024